Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-74

For IIH patients with rapidly deteriorating eyesight, I don't see how any of the other drugs and methods you have mentioned will help as well as Presendin, simply due to the reduction in ICP, I know that I have seen data at least for semaglutide that it has not been shown to reduce ICP. I get why a lot of people are selling right now but if management can figure out how to get 130 patients in with good diagnostic criteria I can see this still succeeding, certainly enough to warrant holding here still, selling at 23c here is what I would expect from holders if the trial had actually failed already. I could be wrong, we'll see